- Home
- TRDA vs ACB Comparison
TRDA vs ACB Comparison
Compare TRDA & ACB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- TRDA
- ACB
- Stock Information
- Founded
- TRDA 2016
- ACB 2013
- Country
- TRDA United States
- ACB Canada
- Employees
- TRDA N/A
- ACB N/A
- Industry
- TRDA Biotechnology: Pharmaceutical Preparations
- ACB Pharmaceuticals and Biotechnology
- Sector
- TRDA Health Care
- ACB Health Care
- Exchange
- TRDA Nasdaq
- ACB Nasdaq
- Market Cap
- TRDA 235.4M
- ACB 256.5M
- IPO Year
- TRDA 2021
- ACB N/A
- Fundamental
- Price
- TRDA $6.95
- ACB $4.95
- Analyst Decision
- TRDA Strong Buy
- ACB
- Analyst Count
- TRDA 3
- ACB 0
- Target Price
- TRDA $25.67
- ACB N/A
- AVG Volume (30 Days)
- TRDA 187.5K
- ACB 1.7M
- Earning Date
- TRDA 11-06-2025
- ACB 11-05-2025
- Dividend Yield
- TRDA N/A
- ACB N/A
- EPS Growth
- TRDA N/A
- ACB N/A
- EPS
- TRDA N/A
- ACB N/A
- Revenue
- TRDA $79,476,000.00
- ACB $262,403,032.00
- Revenue This Year
- TRDA N/A
- ACB $9.42
- Revenue Next Year
- TRDA N/A
- ACB $5.72
- P/E Ratio
- TRDA N/A
- ACB N/A
- Revenue Growth
- TRDA N/A
- ACB 28.58
- 52 Week Low
- TRDA $4.93
- ACB $3.42
- 52 Week High
- TRDA $21.79
- ACB $6.91
- Technical
- Relative Strength Index (RSI)
- TRDA 60.76
- ACB 43.05
- Support Level
- TRDA $6.60
- ACB $4.90
- Resistance Level
- TRDA $7.54
- ACB $5.29
- Average True Range (ATR)
- TRDA 0.43
- ACB 0.25
- MACD
- TRDA 0.06
- ACB -0.07
- Stochastic Oscillator
- TRDA 70.38
- ACB 14.78
About TRDA Entrada Therapeutics Inc.
Entrada Therapeutics Inc is a clinical-stage biopharmaceutical company. It aims to transform the lives of patients by establishing a new class of medicines that engage intracellular targets that have long been considered inaccessible. The Company's Endosomal Escape Vehicle (EEV)-therapeutics are designed to enable the efficient intracellular delivery into a variety of organs and tissues, resulting in an improved therapeutic index and protein-based programs for the potential treatment of neuromuscular and ocular diseases, among others. Its oligonucleotide programs are in development for the potential treatment of people living with Duchenne, which are exon 44, 45, 50, and 51 skipping amenable. It has partnered to develop a clinical-stage program, VX-670, for myotonic dystrophy type 1.
About ACB Aurora Cannabis Inc.
Aurora Cannabis Inc headquartered in Edmonton, Canada, cultivates and sells medicinal and recreational cannabis through a portfolio of brands that includes Drift, San Rafael '71, Daily Special, Whistler, Being, and Greybeard. Although the company operates in Canada, it has expanded internationally through medical cannabis exporting agreements. The company opertes in Canada, Europe, Australia, and Others, with majority revenue from Canada.